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Abstract
The identification and characterization of viral epitopes across the Human Leukocyte Antigen
(HLA) polymorphism is critical for the development of actives-specific or adoptive immunotherapy
of virally-mediated diseases. This work investigates whether cytokine mRNA transcripts could be
used to identify epitope-specific HLA-restricted memory T lymphocytes reactivity directly in fresh
peripheral blood mononuclear cells (PBMCs) from viral-seropositive individuals in response to ex
vivo antigen recall. PBMCs from HLA-A*0201 healthy donors, seropositive for Cytomegalovirus
(CMV) and Influenza (Flu), were exposed for different periods and at different cell concentrations
to the HLA-A*0201-restricted viral FluM158–66 and CMVpp65495–503 peptides. Quantitative real
time PCR (qRT-PCR) was employed to evaluate memory T lymphocyte immune reactivation by
measuring the production of mRNA encoding four cytokines: Interferon-γ (IFN-γ), Interleukin-2
(IL-2), Interleukin-4 (IL-4), and Interleukin-10 (IL-10). We could characterize cytokine expression
kinetics that illustrated how cytokine mRNA levels could be used as ex vivo indicators of T cell
reactivity. Particularly, IFN-γ mRNA transcripts could be consistently detected within 3 to 12 hours
of short-term stimulation in levels sufficient to screen for HLA-restricted viral immune responses
in seropositive subjects. This strategy will enhance the efficiency of the identification of viral
epitopes independently of the individual HLA phenotype and could be used to follow the intensity
of immune responses during disease progression or in response to in vivo antigen-specific
immunization.
Introduction
T cell-directed active or adoptive immunotherapy is an
emerging treatment option for chronic viral infections,
virally-mediated diseases, and virally-induced cancers.
Several virally-induced cancers are caused by relatively
common latent viral infections. Epstein Barr Virus (EBV)
can induce post-transplant lymphoma [1], Burkitt's lym-
phoma, Hodgkin's disease [2], and nasal pharyngeal
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carcinoma [3]. Simian virus 40 (SV40) has been associ-
ated with mesothelioma [4,5] and Human Papiloma
Virus (HPV) with cervical cancer [6] and it appears that T
cell reactivity may control their growth. Thus, we have
been interested in tools that allow for a simplified and
flexible screening of relevant anti-viral immune responses
in seropositive subjects. Among such methods we found
particularly suitable the detection of cytokine mRNA lev-
els produced by immune cells in response to viral-epitope
stimulation. This method involves the detection of
cytokine mRNA levels after a short-term ex vivo sensitiza-
tion of peripheral blood mononuclear cells (PBMCs)
from seropositive individuals exposed to human leuko-
cyte antigens (HLA)-associated viral-epitopes. Cytokine
transcript levels were assessed by quantitative real-time
PCR (qRT-PCR). Others have used a similar approach to
monitor the kinetics of cytokine induction following pol-
yclonal epitope activation [7,8]. Cytokine transcript meas-
urement by qRT-PCR has also been used to determine the
cytokine profile of tumor microenvironment [9] or to
monitor cancer-specific immune responses [10]. Kam-
mula et al. pioneered cytokine transcript monitoring by
investigating cytokine mRNA expression by melanoma
antigen-specific CD8+ T cells in melanoma metastases
from patients undergoing epitope-specific vaccination
[11]. Recently, cytokine level assessment by qRT-PCR has
been used to monitor immune response to other tumors
such as soft tissue limb sarcomas after loco-regional ther-
apy [12]. Although the assessment of cytokine production
by lymphocytes following stimulation with viral peptides
has been characterized after long term in vitro cell culture
[13], the direct ex vivo reactivation of memory T lym-
phocytes from seropositive healthy donors exposed to
HLA-associated viral epitopes has not been full character-
ized [14,15]. Direct ex vivo sensitization has several advan-
tages over in vitro assays; it is simpler and independent of
biases introduced by exposing immune cells to arbitrary
doses of growth factors routinely used in culture such as
Intereukin-2. This assay is a direct quantitative estimate of
the immune reactivity toward a given epitope. A subtle
but more important advantage of ex vivo testing of
immune reactivity consists in the identification of easily
detectable immune specificities likely to be immunodom-
inant in the context of a given disease and HLA pheno-
type. Thus, such strategy should be considered an easy
screening tool for the identification and characterization
of immunodominant epitopes that can be readily applied
to any individual independently of HLA phenotype
through the utilization of overlapping peptide libraries.
The aim of this study was to characterize the usefulness of
cytokine mRNA determination following exposure of
PBMCs from human viral-seropositive to relevant
epitopes in determining individual immune competence
to known immunodominant determinants. Peptides
from Influenza A virus matrix protein M1 (FluM158–66)
[16], Cytomegalovirus matrix protein 65 (CMVpp65495–
503) [17], and from the Tumor Associate Antigen (TAA)
Mage-12 (Mage12170–178) [18] were used to analyze pep-
tide-specific T cell memory reactivation in three HLA-
A*0201 homozygous healthy donors. The short-term
kinetics of Interferon-γ (IFN-γ), Interleukin-2 (IL-2), Inter-
leukin-4 (IL-4), and Interleukin-10 (IL-10) were deter-
mined by measuring qRT-PCR amplification products.
Monitoring of cytokine mRNA production was performed
at different time points (from 3 to 48 hours), to select the
cytokine with the consistently higher mRNA expression
level within the shortest period and to compare this
molecular response to short-term protein production
evaluated by flow cytometry and ELISA.
The study found that mRNA cytokine analysis of seropos-
itive subjects after ex vivo viral and/or tumor peptide expo-
sure is a simple and valid alternative to other methods
that test epitope-induced T lymphocyte reactivation. The
simplicity and sensitivity of this method in identifying
immune dominant epitopes makes it suitable for the
investigation of clinically relevant T cell response.
Material and Methods
Peptide synthesis, reconstitution and storage
The HLA-A*0201-restricted Influenza A virus matrix pro-
tein M158–66 peptide (FluM158–66, GILGFVFTL), the HLA-
A*0201-restricted CMV phosphorylated matrix protein
65495–503 peptide (CMVpp65495–503, NLVPMVATV), and
the HLA-Cw*0702-restricted irrelevant peptide Mage-12
(Mage12170–178,  VRIGHLYIL), were synthesized with a
purity from 90 to 100% as determined by High Pressure
Liquid Chromatography (HPLC) analysis (Princeton Bio-
molecules, Langhorne, PA, USA). Each peptide was dis-
solved in 25% dimethyl sulfoxide (DMSO) at the final
concentration of 1 mg/mL. Up to 50% DMSO was added
to those mixtures of peptide that did not dissolve imme-
diately. The peptide solutions were stored at 4°C and
replaced every month.
Donor Selection
After obtaining informed consent, a lymphapheresis was
performed on four healthy subjects at the Department of
Transfusion Medicine (DTM), Warren G. Magnuson Clin-
ical Center (CC), NIH, Bethesda, Maryland using a
CS3000 Plus blood cell separator (Fenwal, Baxter Health-
care Corporation, Deerfield, IL). All donors were HLA-
A*0201 homozygous. High resolution HLA class I geno-
typing was performed by sequence-specific PCR using
genomic DNA (HLA Laboratory, DTM, CC, NIH,
Bethesda, MD). The presence of IgG and IgM CMV anti-
bodies in each donor was analyzed by passive latex agglu-
tination (CMVSCAN kit, Becton Dickinson Microbiology
System, Cockeysville, MD). Two of the three donors wereJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/12
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seropositive for CMV. The donors were not tested for anti-
bodies to Influenza A since almost all individuals are
seropositive.
Preparation of PBMCs for qRT-PCR kinetic by ex vivo 
sensitization (EVS)
PBMCs from apheresis products were separated from red
blood cells and platelets by Ficoll (Pharmacia Biotech,
Wilkstrom, Sweden) density gradient centrifugation. To
eliminate residual erythrocytes, an ACK Lysis Buffer (Bio
Whittaker, Walkersville, MD) at 1:10 dilution was used
while platelets were removed by washing cells twice in
HBSS (Biofluid, Rockville, MD) at 800 RPM for 10 min.
For the short-term qRT-PCR assays, immediately after
PBMCs were isolated, cells were plated in a 96 U-bottom
well plate with RPMI (Biofluid, Rockville, MD) complete
medium (10% human serum, Gemini Bio-Products,
Woodland, CA; supplemented with 1% HEPES, Biofluid)
at concentrations of 1 × 105, 2 × 105, 1 × 106, 2 × 106cells/
200µl (starting concentrations of 5 × 105, 1 × 106, 5 × 106,
1 × 107cell/ml). 2 × 105cells/200µl has been considered
the standard concentration of cells enable to produce a
significant amount of IFN-γ transcripts, as previously
reported [11] The cells were incubated overnight (18
hours) at 37°C (humidity 90%, CO2 5%) to minimize
background expression of cytokine due to lymphocyte
manipulation. The next day, the PBMCs were directly
exposed to individual peptides at a final concentration of
1  µl/mL and incubated at 37°C from 3 to 48 hours
according to experimental conditions. After each incuba-
tion period the cells were harvested and used for the meas-
urement of cytokine transcription by qRT-PCR following
total RNA extraction and cDNA synthesis.
Total RNA extraction
After incubation, cells where harvested, washed, and total
RNA was extracted using an RNeasy Mini Kit (Qiagen,
Valencia, CA) following the manufacturer's instructions.
To optimize lysis and homogenization when greater than
or equal to 1 × 107 cells were tested, 700 µl of lysis buffer
was used. Total RNA was eluded from columns into a final
volume of 30 µl RNase free water and stored at -80°C or
immediately used for cDNA synthesis.
Complementary DNA synthesis
One to 5 µg total RNA stored at -80°C or rested at 4°C (on
ice) immediately after extraction were transcribed into
cDNA using the SuperScript pre-amplification system
(Invitrogen, Carlsbad, CA). Briefly, total RNA was heated
at 70°C for 10 minutes with 1 µl oligo (dT) primers (0.5
µg/µl) in a final volume of 12 µl. After cooling samples at
4°C for 1 min, 7 µl of RT-PCR mixture (2 µl 10 × RT
Buffer, 2 µl 25 mmol of MgCl2, 1 µl dNTP 10 mmol, and
2 µl 1 M DTT) were added to samples. They were held at
42°C for 5 min. Then, 1 µl Superscript RT II (50 U/µl) was
added to each sample (final volume 20 µl) and cDNA syn-
thesis was performed using these PCR parameters: 42°C
for 50 min and 70°C for 15 min. The samples were thus
held at 37°C for 20 min with 1 µl RNase to avoid RNA
contamination. Synthesized cDNA was stored at -20°C
until use.
Quantitative Real Time Polymerase Chain Reaction (qRT-
PCR)
Measurement of cytokine mRNA expression by qRT-PCR
was performed utilizing an ABI prism 7900 Sequence
Detection System (Applied Biosystem, Foster City, CA).
IFN-  IL-2, IL-4, IL-10, and  -actin genes primers and Taq-
Man probes (Applied Biosystem, Foster City, CA) (Table
1) [9,19] were designed to span exon-intron junctions in
order to prevent amplification of genomic DNA and to
produce amplicons <150 base pairs (bp) enhancing the
efficiency of PCR amplification. TaqMan probes were
labeled at the 5'-end with the reporter dye molecule FAM
(6-carboxyfluorescein; emission λmax = 518 nm) and at
the 3'-end with the quencher dye molecule TAMRA (6 car-
boxytetramethylrhodamine; emission λmax = 582 nm). In
order to create a standard curve, the cDNA was generated
by reverse transcription using a technique identical with
the one used for the preparation of test cDNA. Thereafter,
cDNA of IFN-  IL-2, IL-4, IL-10, and  -actin genes was
amplified by means of regular PCR using the same prim-
ers designed for the qRT-PCR and following these param-
eters: 10 min at 95°C (1 cycle), 30 sec at 95°C, 30 sec at
60°C and 2.5 min at 72°C (40 cycles) and 5 min at 72°C
(1 cycle); final volume 50 µl. Amplified cDNA was then
purified and quantitated by spectrophotometry (OD260).
The number of cDNA copies was calculated using the
molecular weight of each gene amplicon. Serial dilutions
of the amplified gene at known concentrations were tested
by qRT-PCR. Quantitative RT-PCR reactions of cDNA
specimens and cDNA standards were conducted in a total
volume of 50 µl with 1× TaqMan Master Mix (Applied
Biosystem, Foster City, CA) and primers and probes at
optimized concentrations (primer 400 nmol and probe
200 nmol) in a 96-well optical reaction plate (Applied
Biosystem, Foster City, CA). Thermal cycler parameters
were 2 min at 50°C, 10 min at 95°C, and 40 cycles involv-
ing denaturation at 95°C for 15 sec and annealing/exten-
sion at 60°C for 1 min; final volume 50 µl. Real time
monitoring of fluorescent emission from the cleavage of
sequence specific probes by the nuclease activity of Taq
polymerase allowed definition of the threshold cycle dur-
ing the exponential phase of amplification. Standard
curves generated for IFN-  IL-2, IL-4, IL-10, and  -actin
genes were found to have excellent PCR amplification effi-
ciency (90–100%; 100% indicates that after each cycle the
amount of template is doubled) as determined by the
slope of the standard curves. Linear regression analysis of
all standard curves was > 0.99. Standard curve
γ  β
γ  β
γ  βJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/12
Page 4 of 11
(page number not for citation purposes)
extrapolation of gene copy number was performed for all
genes studied. Normalization of values was performed by
dividing the copies of the genes of interest (IFN-γ, IL-2, IL-
4 and IL-10) by the copies of the reference gene (β-actin).
All standard and sample PCR assays were performed in
triplicate and reported as the average.
Intracellular staining (ICS) assay
Freshly isolated PBMCs from seropositive donors at a con-
centration of 1.5 × 106  cells/ml of RPMI complete
medium (without HEPES, Biofluid, Rockville, MD) were
rested overnight in a 14 mL polypropylene tube (Becton
Dickinson, Franklin Lakes, NJ) and then stimulated with
peptide at a final concentration of 10 µg/mL each tube.
One hour after cell activation, Brefeldin A (Sigma, Saint
Louis, MI) at a final concentration of 10 µg/mL was added
to each tube culture. After 5 more hours (6 hours total)
cells were transferred to 5 mL polsterene round bottom
tubes (Becton Dickinson, Franklin Lakes, NJ) and cell
incubation was stopped washing cells in 2 mL cold PBS
for 5 min (1500, 4°C). Pellets were re-suspended in 1 mL
PBS containing 1 mmol EDTA and tubes were incubated
at 37°C for 10 min to detach adherent cells. After washing
cells with 2 mL cold FACS buffer (PBS plus 0.5%BSA) by
centrifugation (5 min, 1500, 4°C), cells were maintained
in a 100 mL suspension for monoclonal antibodies
(MoAb) extra-cellular staining. Cells were stained with 10
µl of CD3-PE and 10 µl CD8-PerCP (BD, Bioscience, San
Jose, CA) for 15 min at 4°C (on ice) in the dark. After sur-
face staining, 2 mL of BD FACS Lysing Solution (BD, Bio-
science, San Jose, CA) at 1:10 dilution in PBS was added
to each tube and the cells were washed by centrifugation
(5 min, 1500, 4°C). Permeabilization of cells was per-
formed by re-suspending cells in 500 µl of FACS Permea-
bilizing Solution 2 (BD, Bioscience, San Jose, CA) at 1:10
dilution in DEPC water, vortexing them for 30 sec and
incubating them at room temperature (RT) for 10 min.
The cells were thus washed twice by centrifugation (2 mL
cold FACS Buffer, 5 min, 1500, 4°C). For intracellular
staining, the cells were stained with either 20 µl of human
anti IFN-γ-FITC or mouse IgG1 isotype-FITC (BD, Bio-
science, San Jose, CA) and incubated for 30 minutes at
4°C (on ice) in the dark. After staining, the cells were
washed once (2 mL cold FACS Buffer, 10 min, 1500, 4°C)
and immediately analyzed on a flow cytometer or fixed in
200 µl 4% paraformaldehyde in PBS solution, kept at 4°C
in the dark and analyzed later.
Peptide-specific ex vivo (EVS) and in vitro sensitization 
(IVS) for protein release kinetics
Cell supernatants from ex vivo stimulated PBMCs sensi-
tized at different concentrations and times of exposure
were used for the measurement of cytokine protein release
with an enzyme-linked immunoabsorbent assay (ELISA)
kit (Endogen, Woburn, MA). Briefly, after each time point
harvested cells were used for mRNA cytokine transcription
while supernatant were used for protein release detection.
In parallel, a 2-week in vitro sensitization was performed
using PBMCs from CMV-seropositive donors. Cells were
plated at a concentration of 3 × 106/2 ml of medium per
well in a anti-human CD3 T-cell activation 24-well plate
(Becton Dickinson, Bedford, MD) and directly stimulated
with 3 µl/mL of peptide (day 0). One day later (day 1),
recombinant human interleukin-2 (rhIL-2, 100 U/ml)
and recombinant human interleukin-7 (rhIL-7, 10 ng/ml)
(PeproTech, Rocky Hill, NJ) were added to the cell culture.
rhIL-2 only (100 U/ml) was continuously administered
Table 1: Quantitative real time PCR primers and probes for evaluating the four cytokines of interest and the reference genes.
Gene Primers and Probe
β-actin (f) 5'-GGCACCCAGCACAATGAAG-3'
(r) 5'-GCCGATCCACACGGAGTACT-3'
(p) 6FAM-TCAAGATCATTGCTCCTCCTGAGAGCGC-TAMRA
IFN-γ (f) 5'-AGCTCTGCATCGTTTTGGGTT-3'
(r) 5'-GTTCCATTATCCGCTACATCTGAA-3'
(p) 6FAM-TCTTGGCTGTTACTGCCAGGACCCA-TAMRA
IL-2 (f) 5'-ACCAGGATGCTCACATTTAAGTTTT-3'
(r) 5'-GAGGTTTGAGTTCTTCTTCTAGACACTG-3'
(p) 6FAM-CATGCCCAAGAAGGCCACAGAACTG-TAMRA
IL-4 (f) 5'-GCGATATCACCTTACAGGAGATCAT-3'
(r) 5'-GTTACGGTCAACTCGGTGCA-3'
(p) 6FAM-TGCTGCCAACTGGCGCTCCTCC-TAMRA
IL-10 (f) 5'-GCCGTGGAGCAGGTGAAG-3'
(r) 5'-GAAGATGTCAAACTCACTCATGGCT-3'
(p) 6FAM-TGCCTTTAATAAGCTCCAAGAGAAAGGCATCTACA-TAMRA
(f) forward primer; (r) reverse primer; (p) probe * These primers and probes have been previously published [9,19]Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/12
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every other day. At day 15, each group of cells was washed
and directly re-stimulated in 2 mL of fresh medium with
3 µl/mL of peptide or was not re-stimulated. Eighteen
hours after peptide boosting, the in vitro sensitized PBMCs
were harvested. Supernatants were collected to measure
IFN-γ protein release using the ELISA assay.
Data analysis
Quantitative RT-PCR results were reported as the number
of IFN- , IL-2, IL-4, and IL-10 gene copies normalized by
105β-actin gene copies and plotted against the different
times of exposure. The cytokine production, as shown,
represents the mRNA copy number of the gene of interest
from stimulated cells relative to the copy number of the
gene of interest from unstimulated cells, in both cases
after normalization by the gene of reference (β-actin). Fig-
ure 3 shows the results as mRNA copy numbers corrected
by β-actin. Student's t test was used to compare cytokine
mRNA release as well as cytokine protein expression by
PBMCs stimulated under different conditions. ELISA
results were extrapolated from a standard curve generated
by linear regression. Three-color flow cytometry was per-
formed using a FACS-Calibur flow cytometer and data
were analyzed using CellQuest software. For each analy-
sis, 250,000 events were acquired. A light scatter region
was designed to include only viable lymphocytes. FACS
analysis was performed on gated CD3bright  expression
allowing the exclusion of residual contaminating cells.
Results
Quantification of human IFN-γ, IL-2, IL-4, and IL-10 
mRNAs after ex vivo epitope stimulation of PBMCs
To determine the best target cytokine for assessing
epitope-specific memory T lymphocytes reactivation, gene
amplification of four cytokine, IFN-γ, IL-2, IL-4, and IL-10
was estimated by qRT-PCR. Cytokine mRNA levels were
measured over 48 hours following ex vivo peptide expo-
sure of PBMCs from three HLA-A*0201 subjects. Since
approximately 90% of the population has been exposed
to Influenza, we initially analyzed the response to the pep-
tide FluM158–66 (GILGFVFLT). After 3 hours large quanti-
ties of IFN-γ transcripts were detected, but little or no IL-2,
The kinetics of IFN-γ, IL-2, IL-4 and IL-10 transcription following FluM158–66 stimulation of three HLA-A*0201 donors Figure 1
The kinetics of IFN-γ, IL-2, IL-4 and IL-10 transcription following FluM158–66 stimulation of three HLA-A*0201 
donors. The standard concentration of 2 × 105cells/200µl was ex vivo exposed to the peptide. At hour 3, IFN-γ transcript pro-
duction precedes IL-2, IL-4 and IL-10. At hour 12 there is consistent production of Th1 (IFN-γ, IL-2) cytokines. IL-4 and IL-10 
transcript production increases above the baseline levels from 24 to 48 hours. For each donor and at each time point mRNA 
copy numbers were calculated relative to unstimulated cells after normalization by β-actin. The result represents the mean ± 
SEM of averages of combined values of three independent experiments carried out on each of the three donors.
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IL-4, and IL-10. Maximum levels of IL-2 transcripts were
detected at hour 24. IL-4 and IL-10 transcripts levels
increased above baseline level after 24 hours and contin-
ued to rise up to 48 hours from stimulation (Fig 1).
Although IFN-γ transcript rapidly decreased during the 48
period, significant levels were still detectable at hour 12 in
all three donors. These results show that following ex vivo
peptide stimulation of memory T cells, IFN-γ precedes IL-
2, IL-4, and IL-10 transcription.
Human IFN-γ transcript quantification following 
stimulation with CMVpp65495–503, FluM158–66 or 
Mage12170-178
Since IFN-γ transcripts were the earliest and most abun-
dant transcripts, we further characterized IFN-γ mRNA
expression in response to other ex vivo peptide stimula-
tions. The three HLA-A*0201 donors were stimulated
with CMVpp65495–503  (NLVPMVATV), FluM158–66
(GILGFVFTL), and the irrelevant Mage170–178  (VRIGH-
LYIL) peptides. Analysis of the response curves showed
that CMV stimulation did not result in the same transcrip-
tion kinetics of Flu (Fig 2, donor A and B in panel B). IFN-
γ transcription levels upon Flu stimulation were greatest
after 3 hours and showed a linear reduction (Fig 2, panel
A). In contrast, IFN-γ transcription levels after CMV stim-
ulation varied but did not differ significantly between 3,
6, and 12 hours before falling drastically after 24 hours
(Fig 2, panel B). Stimulations of all three donors with the
irrelevant Mage170–178 and stimulation of the CMV-seron-
egative donor with CMVpp65495–503 failed to induce IFN-
γ transcription at any time point (Fig 2, panel C and donor
C in panel B).
IFN-γ transcript production by memory T lymphocytes following ex vivo FluM158–66, CMVpp65495–503, and Mage12170–178 peptide  stimulation Figure 2
IFN-γ transcript production by memory T lymphocytes following ex vivo FluM158–66, CMVpp65495–503, and 
Mage12170–178 peptide stimulation. In the period of 3 to 12 hours, IFN-γ cytokine production was inversely proportional 
to the time of exposure during FluM158–66 stimulation (panel A), maintained an average level during CMVpp65495–503 stimulation 
(panel B) or was not produced during Mage12170–178 exposure (panel C). The results are expressed in mRNA copy numbers 
calculated relative to unstimulated cells after normalization by β-actin and represent the expressed values from each donor 
tested. Panel D specifically shows the kinetics of a representative donor (donor B) after the different viral peptide exposures 
relative to the negative value (unstimutated cells).
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Correlation between IFN-γ transcription and cell 
concentration following ex vivo CMVpp65495-503 
stimulation of PBMCs from HLA-A*0201 CMV-
seropositive and seronegative donors
To investigate the reasons for differences observed in the
kinetics of IFN-γ transcription between CMVpp65495–503
and FluM158–66 peptide stimulation, we tested whether
concentration of responded cells could affect such kinet-
ics. Thus, the correlation between IFN-γ mRNA produc-
tion and number of lymphocytes exposed to
CMVpp65495–503  was explored. PBMCs from all three
donors were stimulated ex vivo at various concentrations
of 1 × 105, 2 × 105, 1 × 106, 2 × 106cells/200µl with
CMVpp65495–503 and evaluated at 3, 12 and 24 hours. We
found that at the 3-hour time point IFN-γ transcription
increased directly with cell concentration (Fig 3, panel A),
but after 12 hours IFN-γ transcription reached a peak at
intermediate concentrations (2 × 105 cells/200µl) (Fig 3,
panel B). At hour 24, IFN-γ transcription was low and sim-
ilar at all cell concentrations (Fig 3, panel C). Interestingly
Effect of cell concentration on the specific kinetics of IFN-γ transcript production during CMVpp65495–503 peptide stimulation Figure 3
Effect of cell concentration on the specific kinetics of IFN-γ transcript production during CMVpp65495–503 pep-
tide stimulation. Different concentrations of PBMCs from two CMV seropositive donors and one CMV seronegative donor 
were ex vivo peptide stimulated and analyzed at hour 3, 12 and 24 of sensitization for IFN-γ transcript production. For all 
donors tested, panels A, B and C show IFN-γ transcript production for each time of exposure (hour 3, 12 and 24, respectively) 
relative to cell concentration. Inversely, panels D, E and F show IFN-γ transcription for each quantity of stimulated cells relative 
to the three times of exposure only for the two seropositive donors. All results represent the mean ± SEM of three independ-
ent experiments carried out in triplicate.
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in this experiment, the kinetics of IFN-γ transcription were
similar to the results observed previously with
CMVpp65495–503 stimulation (Fig 2, panel B) only when
cells were tested at a concentration of 1 × 105 (data not
shown) and 2 × 105/200µl (Fig 3, panel D). Conversely,
the slopes of both curves obtained at concentrations of 1
× 106 and 2 × 106 cells/200µl (Fig 3, panel E and F) fol-
lowed a decreasing IFN-γ transcription kinetics similar to
that displayed by flu stimulation (Figure 2, panel A).
Extra-cellular and intra-cellular release of IFN-γ protein 
following ex vivo peptide-stimulated PBMCs
To determine if other measures of IFN-γ could be used to
effectively evaluate T cell activation following ex vivo stim-
ulation, the kinetics of IFN-γ protein release was assessed.
Following various durations of exposure of PBMCs to
either FluM158–66 or CMVpp65495–503, cell supernatants
were analyzed for IFN-γ protein release. From 3 through
48 hours after sensitization, IFN-γ protein release by
PBMCs from the seropositive subjects was not or only
slightly different from the protein release by PBMCs from
the seronegative subject (Fig 4, panels A and B). In con-
trast, when the cells where sensitized for 2 weeks and
boosted with the same peptides, IFN-γ protein production
was 10-fold higher, confirming that it is possible to use
protein production to estimate the T cell response when in
vitro  cell sensitization is carried out (Fig 4, panel C).
Conversely, the IFN-γ intra-cellular staining was consist-
ently positive upon ex vivo stimulation with CMVpp65495–
503 peptide and moderately positive with FluM158–66 pep-
tide (Fig 5). No evidence of intra-cellular protein
accumulation was observed at different time points tested
Assessment of the IFN-γ protein release kinetics by ex vivo peptide-stimulated PBMCs Figure 4
Assessment of the IFN-γ protein release kinetics by ex vivo peptide-stimulated PBMCs. Two donors, one CMV 
seropositive and one CMV seronegative, were exposed at various durations of time to both FluM158–66 and CMVpp65495–503 
peptides and cell supernatants were analyzed for IFN-γ protein release (panel A and B). Panel C shows the protein release 
from both FluM158–66 and CMVpp65495–503 2-week sensitized PBMCs from the CMV seropositive donors either after an 18-
hour peptide re-exposure or after no peptide re-exposure. Results represent the mean ± SEM of three independent experi-
ments carried out in triplicate.
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before the standard 6 hour sensitization (data not
shown).
Discussion
Memory T lymphocytes represent a population of active
immune effectors that retain a prior stimulus and evoke a
stronger and more rapid immune response after a second-
ary immunization. Among the cytokines produced after
immune reactivation, IFN-γ is released within a few hours
after stimulation. IFN-γ is produced in response to anti-
gen-specific stimulation by cytotoxic T lymphocytes
(CTLs) and inflammatory CD4+ T cells (Th1) and their
precursor (Th0) or nonspecifically by natural killer (NK)
cells [20]. Its levels are an indicator of the immune activity
of armed effector T cells.
The evaluation of memory T cell reactivation can be per-
formed between 3 to 12 hours irregardless of the source of
peptides. Initially, cytokine mRNA transcription was
tested against 2 × 105 PBMCs by using FluM158–66. Flu sen-
sitization displayed the greatest rates of IFN-γ release 3
hours after stimulation. In spite of the inverse correlation
of the transcript levels to the time of exposure, FluM158–66
maintained significant amounts of IFN-γ transcription
during the 3 to 12 hour period. In contrast, peak IL-2, IL-
4 and IL-10 mRNA did not occur until 24 to 48 hours after
peptide sensitization. Conversely, CVMpp65495–503 stimu-
lation displayed different IFN-γ mRNA transcription
kinetics regardless of cell concentration and periods of
exposure. However, studies of the kinetics of expression of
the four cytokines revealed that IFN-γ mRNA can be
detected either after both FluM158–66 and CVMpp65495–503
peptide stimulation between 3 and 12 hours at the stand-
ard concentration of 2 × 105 cells.
These results suggest that it is possible to vary the time of
cell analysis from 3 to 12 hours after peptide stimulation.
In some cases it may be necessary to analyze cells more
than 3 hours after stimulation due to variations in the
interactions between HLA antigens and peptides. Our
group has already found that analysis of cells 5 hours after
peptide exposure enhanced the ability to detect HLA-
A*0301, A*3301, and A*3303 interactions with CMV
pp65 peptides [21,22].
IFN-γ Intracellular Staining (ICS) after the standard six hours peptide exposure Figure 5
IFN-γ Intracellular Staining (ICS) after the standard six hours peptide exposure. All donors were exposed to both 
FluM158–66 and CMVpp65495–503 peptides and then analyzed for intracellular IFN-γ protein release. Panel A: FACS analysis was 
conducted on gated CD3 positive lymphocytes after selecting only viable cells (R1 and R2) and plotting CD8 positive (x-axis) 
against either mouse IgG1 isotype-stained (y-axis, upper row) or human anti-IFN-γ-stained (y-axis, lower row) lymphocytes. 
The figure shows one representative experiment of three carried out on each donor. Panel B: IFN-γ ICS results in 3 different 
donors. The calculation of the percentage of antigen-specific T cells was performed based on the CD8 and IFN-γ dot plot data 
according to the following formula: Percentage Ag-specific T-cells = Percentage Upper right quadrant /(Percentage Upper right quadrant + Per-
centage Lower right quadrant)* 100%.
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Different types of assays have been used to identify CTL
specificity by measuring IFN-γ protein levels including
ELISA, ELISPOT and intracellular staining (ICS). While
both ELISA and ELISPOT assays are effective, they have
the major disadvantage of requiring that cells are stimu-
lated and cultured for several days or even weeks before
monitoring immune T cell activity [23]. Moreover, pro-
longed cultures of sensitized cells may lead to the artifac-
tual expansion of irrelevant cell populations. Consistent
with the fact that a 3-hour sensitization is a short time for
mRNA translation and protein production or for the
proliferation of a sub-population of responding memory
T cells [24,25], we found that protein detection assays
failed to detect activated cells when carried out on unex-
panded PBMCs demonstrating the higher sensitivity of
the technique we used to induce and detect a T cell
response after few hours [26-29].
The ancillary use of ICS or IVS protein detection assays to
investigate the specific immune activity of potential
immunodominant peptides is helpful in completing the
understanding of how those peptides work in the context
of specific immune reactivation.
In conclusion, we confirmed that molecular analysis by
qRT-PCR was effective in identifying immune activity of
viral peptides by reactivation of stimulated memory T cell
from seropositive HLA-restricted donors after only 3
hours. The secondary immune response resulted in a
strong Th1 cytokines production (IFN-γ and IL-2) within
few hours. Negative results obtained following tumor-
peptide stimulation of PBMCs from subjects not exposed
to tumor antigens or subjects seronegative for the target
viral antigens confirmed this finding.
By using this method we were able to confirm the immu-
nogenicity of the peptides FluM158–66 and CMVpp65495–
503 [30-32]. The major practical advantage is that it allows
the rapid evaluation of immune memory T cells reactiva-
tion by the detection of specific cytokine gene profiles. It
makes it possible to screen a large number of viral and/or
tumor epitopes and to study their immune activity in a
short period of time, with high specificity and without
handling large quantities of cells. The strong response
after viral restimulation and the ability to use seropositive
donors make this method valuable for any disease-related
viral peptide investigation.
Abbreviations
APC, antigen presenting cells; CMV, Cytomegalovirus;
Flu, Influenza virus; TAA, tumor associated antigens; IVS,
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peripheral blood mononuclear cells
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